Publications

Manuscripts

2018

Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail. 2018;20(5):923-930.2018 2018

Manuscripts

2018

Brew CT, Blake JF, Mistry A, Liu F, Carreno D, Madsen D, Mu Y, Mayo M, Stahl W, Matthews D, Maclean D, Harrison S. Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted Polymer. Pharm Res. 2018;35(4):89. View Online2018 2018

Manuscripts

2018

Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, Hasegawa T, Heerspink HL, Hirayama A, Landman G, Levin A, Nitsch D, Wheeler DC, Coresh J, Hallan SI, Shalev V, Grams ME. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535-1542.2018 2018

Manuscripts

2018

Pitt B, Bushinsky D, Kitzman D, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M. Evaluation of an individualized dose titration regimen of the potassium-binding polymer, patiromer, to prevent hyperkalemia in patients with heart failure and chronic kidney disease initiating spironolactone. ESC Heart Fail. 2018;5(3):257-266. View Online2018 2018

Manuscripts

2018

Pitt B, Bakris G, Weir M, Freeman M, Lainscak M, Mayo M, Garza D, Zawadzki R, Berman L, Bushinsky, D. Long-term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on ACEIs/ARBs: Results from AMETHYST-DN. ESC Heart Fail. 2018 May 16. doi: 10.1002/ehf2.12292 (e-pub). View Online2018 2018

Manuscripts

2018

Pitt B, Garza D. The Tolerability and Safety Profile of Patiromer: A Novel Polymer-Based Potassium Binder for the Treatment of Hyperkalemia. Expert Opin Drug Saf. 2018;17(5):525-535. View Online View Correction2018 2018

Manuscripts

2018

Weir M, Bushinsky D, Benton W, Woods S, Mayo M, Arthur S, Pitt B, Bakris G. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018;131(5):555-564.e3. View Online2018 2018

Manuscripts

2017

Brunelli S, Oestreicher N, Du Mond C, Spiegel D, Winkelmayer WC, Kovesdy CP. Serum-to-dialysate potassium gradient and short-term outcomes in hemodialysis patients. Nephrol Dial Transplant. 2017;epub. View Online2017 2017

Manuscripts

2017

Brunelli SM, Du Mond C, Oestreicher N, Rakov V, Spiegel D. Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval. Am J Kidney Dis. 2017;70(1):21-9. View Online2017 2017

Manuscripts

2017

Chen Y, Sang Y, Ballew SH, Tin A, Chang AR, Matsushita K, Coresh J, Kalantar-Zadeh K, Molnar MZ, Grams ME. Race, serum potassium, and associations with end-stage renal disease and mortality. Am J Kidney Dis. 2017;70(2):244–51. View Online2017 2017

Manuscripts

2017

Clegg DJ, Cody M, Palmer BF. Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia . Mayo Clin Proc. 2017;92(8):1248-60. View Online2017 2017

Manuscripts

2017

Collins A, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bakris G, Bushinsky D. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-21. View Online2017 2017

Manuscripts

2017

Connor EF, Lees I, Maclean D. Polymers as Drugs – Advances in Therapeutic Applications of Polymer Binding Agents. J Polym Sci A Polym Chem. 2017;55(18):3146-57. View Online2017 2017

Manuscripts

2017

Golestaneh L, Alvarez P, Reaven NL, Funk SE, McGaughey KJ, Romero A, Brenner MS, Onuigbo M. All-cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage. Am J Manag Care. 2017;23(10 Sup.):S163-72. View Online2017 2017

Manuscripts

2017

Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, Onuigbo M. Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs. J Clin Pathways. 2017;3(9):40-48. View Online2017 2017

Manuscripts

2017

Hill-Gallant K, Spiegel D. Calcium Balance in Chronic Kidney Disease. Curr Osteoporos Rep. 2017;15(3):214-21. View Online2017 2017

Manuscripts

2017

Kumar R, Kanev L, Woods SD, et al. Managing hyperkalemia in high-risk patients in long-term care. Am J Manag Care. 2017;23:S27-S36. View Online2017 2017

Manuscripts

2017

Lesko LJ, Offman E, Brew CT, et al. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. J Cardiovasc Pharmacol Ther. 2017;22(5):434-446 View Online2017 2017

Manuscripts

2017

Pergola P, Spiegel DM, Warren S, Yuan J, Weir MR. Patiromer Lowers Serum Potassium When Taken Without or With Food: Results from An Open-Label, Randomized, Parallel Group Hyperkalemia Study. Am J Nephrol. 2017;46(4):323-332. View Online2017 2017

Manuscripts

2017

Polson M, Lord TC, Evangelatos T, C. Farnum C, Sproles C, Oestreicher N. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. J Manag Care Spec Pharm. 2017;23(4-a Suppl):S2-S9. View Online2017 2017

Manuscripts

2017

Rafique Z, Weir M, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock W. Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. J Manag Care Spec Pharm. 2017;23(4-a):S10-20. View Online2017 2017

Manuscripts

2017

Weir M, Mayo M, Garza D, Arthur S, Berman L, Bushinsky D, Wilson D, Epstein M. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017;35(Suppl 1):S57-S63. View Online2017 2017

Manuscripts

2016

Bakris GL, et al. Letter to the Editor. J Cardiovasc Dis Diag. 2016;4(2):237. View Online2016 2016

Manuscripts

2016

Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol. 2016;11(10). View Online2016 2016

Manuscripts

2016

Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. Am J Nephrol. 2016;44(5):404-410. View Online2016 2016

Manuscripts

2016

Chang AR, Sang Y, Leddy J, et al. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension. 2016;67:1181-1188. View Online2016 2016

Manuscripts

2016

Chen Y, Chang AR, McAdams DeMarco MA, et al. Serum potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities (ARIC) study. Mayo Clinic Proc. 2016;91(10):1403-1412. View Online2016 2016

Manuscripts

2016

Epstein M, Ed. Hyperkalemia: Current Concepts and Emerging Therapeutic Options. Nephrology News & Issues Special Supplement. 2016;30(4):S1-S31. View Online2016 2016

Manuscripts

2016

Epstein M, Ed. Hyperkalemia: Current Concepts and Emerging Therapeutic Options. Kidney International Supplements. 2016;6(1):1-34. View Online2016 2016

Manuscripts

2016

Epstein M, Alvarez PJ, Reaven NL, et al. Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors. Am J Manag Care. 2016;22(11 - Suppl):S311-324. View Online2016 2016

Manuscripts

2016

Epstein M, Pitt BC. Recent Advances in Pharmacological Treatments of Hyperkalemia: Focus on Patiromer. Expert Opin Pharmacother. 2016;17(10):1435-48. View Online2016 2016

Manuscripts

2016

Li L, Harrison SD, Cope J, et al. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21(5):456-65. View Online2016 2016

Manuscripts

2016

Weir MR, Bakris GL, Gross C, et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016;90(3):696-704. View Online2016 2016

Manuscripts

2015

Bakris GL, Pitt B, Mayo M, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: the AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314(2):151-161. View Online2015 2015

Manuscripts

2015

Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427-33. View Online2015 2015

Manuscripts

2015

Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The Burden of Hyperkalemia in Patients With Cardiovascular and Renal Disease. Am J Manag Care. 2015;21(15):S307-S315. View Online2015 2015

Manuscripts

2015

Epstein M, Reaven NL, Funk SE, et al. Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors. Am J Manag Care. 2015;21(11):S212-S220. View Online2015 2015

Manuscripts

2015

Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057-65. View Online2015 2015

Manuscripts

2015

Pitt B, Weir MR. Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment? Eur J Heart Fail. 2015;(12):216. View Online2015 2015

Manuscripts

2015

Staube B, Reaven N, Funk S. Letter to the Editor (Little et al). Clinical Nephrology. 2015;83(6):380-81. View Online2015 2015

Manuscripts

2015

Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015;372(3):211-21. View Online2015 2015

Manuscripts

2014

Reaven NL, Funk SE, Bakris GL. The Economics of Renoprotective Therapy in Advanced Diabetic Kidney Disease. Am J Pharm Benefits. 2014;6(6):e169-e176. View Online2014 2014

Manuscripts

2012

Buysse JM, Huang I, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol. 2012;8(1):17-28.2012 2012

Manuscripts

2011

Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820-828. View Online2011 2011

Congresses

2018

ANNA

Fogli J, Mayo M, Miyawa J, Ono R, Gross C. In Vitro Total Potassium-Binding Capacity of Patiromer When Mixed with Apple or Cranberry Juice. Presented at 2018 American Nephrology Nurses Association National Symposium. Abstract Poster2018 ANNA 2018

Congresses

2018

ERA-EDTA

Chatoth D, Wahl P, Rakov V, Van Zandt CR, Anastassopoulos KP, Colman S, Knight T, Romero A, Mooney A, Spiegel D. Real-world treatment and clinical outcomes in end-stage renal disease patients with severe hyperkalemia undergoing hemodialysis in the United States. Nephrol Dial Transplant. 2018;33(suppl 1):i218. Abstract2018 ERA-EDTA 2018

Congresses

2018

ERA-EDTA

Rossignol P, Gross C, Mayo M, Warren S, Yuan J, Budden J, Morales E. Effect of patiromer on serum potassium in hyperkalaemic patients with and without obesity: pooled results from the AMETHYST-DN, OPAL-HK and TOURMALINE trials. Nephrol Dial Transplant. 2018;33(suppl 1):i11. Abstract2018 ERA-EDTA 2018

Congresses

2018

ERA-EDTA

Rossignol P, Pignot M, Cornea G, Schulmann T. The dilemma of recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors. a European multi-national targeted chart review. Nephrol Dial Transplant. 2018;33(suppl 1):i154. Abstract2018 ERA-EDTA 2018

Congresses

2018

HFA

Pitt B, Mayo M, Garza D, Arthur S, Lainscak M. Long-term effect of patiromer for hyperkalaemia treatment in patients with HFmrEF and diabetic nephropathy on RAAS Inhibitors. Eur J Heart Fail. 2018;20(suppl S1):591.2018 HFA 2018

Congresses

2018

HFA

Rossignol P, Pignot M, Cornea G, Zakin L, Schulmann T. The dilemma of recurrent hyperkalaemia and use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: a European multi-national targeted chart review. Eur J Heart Fail. 2018;20(suppl S1):254.2018 HFA 2018

Congresses

2018

NKF

Weir M, Mayo M, Yuan J, Conrad A. Consistency of Serum Potassium Effects in Patiromer Clinical Trials. Am J Kidney Dis. 2018;71(4):596. Free online access to abstract at: https://doi.org/10.1053/j.ajkd.2018.02.330 Poster2018 NKF 2018

Congresses

2018

SAEM

Liu M, Rafique Z, Peacock W. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study. Presented at Society for Academic Emergency Medicine 2018 Annual Meeting. View Online2018 SAEM 2018

Congresses

2017

AAHFN

Garza D, Gross C, Mayo M, Yuan J, Wilson D, Weir M, Pitt B. Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors. Heart Lung. 2017;46(3):215. View Online2017 AAHFN 2017

Congresses

2017

ACC

Pitt B, Gross C, Mayo M, Garza D, Yuan J, Wilson D, Weir M . Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors. J Am Coll Cardiol. 2017;69(11):912. View Online2017 ACC 2017

Congresses

2017

AHA

Kloner R, Gross C, Yuan J, Conrad A, Pergola P. Effect of patiromer in hyperkalemic patients with or without RAASi. Circulation. 2017;136(Issue Suppl 1):A14680. See Kloner et al. J Cardiovasc Pharmacol Ther 2018 article.2017 AHA 2017

Congresses

2017

AMCP

Veenstra DL, Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ. A Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. J Manag Care Spec Pharm. 2017;23(3-a):S73-4. View Online2017 AMCP 2017

Congresses

2017

AMCP

Golestaneh L, Alvarez P, Reaven N, Funk S, McGaughey K, Onuigbo M. Healthcare Cost Rises Exponentially by Stage of Chronic Kidney Disease. Academy of Managed Care Pharmacy 2017 - 29th Annual Meeting & Expo. 2017. See Golestaneh et al. Am J Manag Care 2017 article.2017 AMCP 2017

Congresses

2017

AMCP

Johnson ES, Yang X, Thorp ML, Oestreicher N, Smith DH. Hyperkalemia in heart failure was associated with excess emergency department visits and hospital admissions. J Manag Care Spec Pharm. 2017;23(3-a):S72-3. View Online2017 AMCP 2017

Congresses

2017

AMCP-Nexus

Desai N, Reed P, Oestreicher N, Alvarez P, Owens MK. Economic Implications of Hyperkalemia in a US Managed Medicaid Population. J Manag Care Spec Pharm. 2017;23(10-a):S14. View Online2017 AMCP-Nexus 2017

Congresses

2017

ASN

Chatoth DK, Wahl PM, Rakov V, Van Zandt CR, Anastassopoulos KP, Colman S, Knight T, Oestreicher N, Mooney A, Spiegel DM, Weir MR. Outcomes in ESRD Patients on Hemodialysis Taking Patiromer for Hyperkalemia. Clin J Am Soc Nephrol. 2017;28(Abstract Edition):301. View Online2017 ASN 2017

Congresses

2017

ASN

Rowan CG, Winkelmayer WC, Oestreicher N, Rakov V, Connaire JJ, Spiegel DM, Kovesdy CP. Patient Characteristics and Correlates of Patiromer Initiation for Hyperkalemia in Hemodialysis. Clin J Am Soc Nephrol. 2017;28(Abstract Edition):301. View Online2017 ASN 2017

Congresses

2017

ASN

Bushinsky D, Spiegel D, Yuan J, Warren S, Pergola P. Effects of the Potassium Binding Polymer Patiromer on Markers of Mineral Metabolism. Clin J Am Soc Nephrol. 2017;28(Abstract Edition):54. View Online2017 ASN 2017

Congresses

2017

CRS

Maclean D, Li L, Madsen D, Park C, Lee L, Salaymeh F, Harrison SD. Polymers as drugs. The development of patiromer for lowering serum potassium concentration in patients with hyperkalemia. Presented at Controlled Release Society - 44th Annual Meeting. 2017.2017 CRS 2017

Congresses

2017

EASD

Rossignol P, Gross C, Spiegel DM, Yuan J, Pergola PE. Serum potassium control and patiromer taken without or with food in hyperkalemic patients with diabetes. Presented at European Association for the Study of Diabetes - 53rd Annual Meeting. 2017. View Online2017 EASD 2017

Congresses

2017

ERA

Chatoth DK, Wahl PM, Rakov V, Van Zandt C, Anastassopoulos KP, Colman S, Knight T, Hill N, Mooney A, Spiegel DM. Real-world outcomes of hyperkalemia management with patiromer in end-stage renal disease patients undergoing hemodialysis in the United States. Nephrol Dial Transplant. 2017;32(suppl_3):iii657. View Online2017 ERA 2017

Congresses

2017

ERA

Haas JS, Braunhofer PG, Zakin LB, Rakov V, Hardt T, Meise D, Maas C, Braun S. Hyperkalemia incidence and patterns of care in patients treated with renin-angiotensin-aldosterone system inhibitors - a retrospective claims data analysis to assess healthcare outcomes in Germany. Nephrol Dial Transplant. 2017;32(SUPPL_3):iii574. (This publication was from the Vifor German Affiliate) View Online2017 ERA 2017

Congresses

2017

ERA

Rowan CG, Kovesdy CP, Du Mond C, Oestreicher N, Spiegel DM, Winkelmayer WC. Comparison of Potassium Values Before and After Patiromer Initiation Among Patients Recieving Chronic Hemodialysis in the United States. Nephrol Dial Transplant. 2017;32(SUPPL_3):iii578. View Online2017 ERA 2017

Congresses

2017

ERA

Bushinsky D, Romero A, Arthur S, Mayo M, Ketteler M. Effect of Patiromer on Serum Potassium in Hyperkalemic Patients with Severe CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN. Nephrol Dial Transplant. 2017;32(suppl_3):iii89-iii91. View Online2017 ERA 2017

Congresses

2017

ESC

Pina IL, Garza D, Mayo M, Warren S, Yuan J, Romero A, Cleland J. Effect of patiromer on serum K+ in hyperkalaemic patients with HF: Pooled results from AMETHYST-DN, OPAL-HK and TOURMALINE. Eur Heart J. 2017;38(suppl_1):44. View Online2017 ESC 2017

Congresses

2017

HFA

Pitt B, Garza D, Zawadzki R, Romero A, Conrad A, Lainscak M. Long-term effects of patiromer for hyperkalemia treatment in patients with HFrEF and diabetic nephropathy on RAASi. Eur J Heart Fail. 2017;19(Suppl. S1):55. View Online2017 HFA 2017

Congresses

2017

HFSA

Pina IL, Garza D, Mayo M, Warren S, Yuan J, Romero A, Cleland JG. Effect of patiromer on serum K+ in hyperkalemic patients with heart failure (HF): pooled results from the AMETHYST-DN, OPAL-HK and TOURMALINE Trials. J Card Fail. 2017;23(8 Supplement):S21. View Online2017 HFSA 2017

Congresses

2017

IAC

Weir M, Spiegel D, Wilson D, Benton W, Yuan J, Gross C. Aldosterone, Renin, and Blood Pressure During Patiromer Treatment of Hyperkalemia in CKD. IAC 42nd program book. 2017. See Weir et al. Kidney Int 2016 article.2017 IAC 2017

Congresses

2017

IAC

Pitt B, Gross C, Mayo M, Garza D, Yuan J, Wilson D, Weir M . Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors. IAC 42nd program book. 2017.2017 IAC 2017

Congresses

2017

ISPOR

Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Assessing the Cost-effectiveness of Patiromer Plus Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Value Health. 2017;20(5):A271. View Online2017 ISPOR 2017

Congresses

2017

NKF

Pergola PE, Spiegel DM, Warren S, Yuan J, Weir M. Patiromer Lowers Serum Potassium (K) When Taken With or Without Food. Am J Kidney Dis. 2017;69(4):A76. See Pergola et al. Am J Nephrol 2017 article.2017 NKF 2017

Congresses

2017

TAP

Weir M, Spiegel DM, Warren S, Yuan J, Pergola PE. Patiromer and Serum Potassium Control in a Hispanc/Latino Population. Presented at World Congress of Nephrology - 2017. 2017. View Online2017 TAP 2017

Congresses

2017

TAP

Li L, Park C, Lee L, Salaymeh F, Madsen D, Harrison SD. The development of patiromer for lowering serum potassium concentration in patients with hyperkalemia. Presented at 10th Global Summit on Toxicology and Applied Pharmacology. 2017.2017 TAP 2017

Congresses

2017

WCN

Golestaneh L, Alvarez P, Reaven N, Funk S, McGaughey K, Romero A, Onuigbo M. Healthcare Costs Accelerate with Chronic Kidney Disease Progression. World Congress of Nephrology - 2017. 2017. See Golestaneh et al. Am J Manag Care 2017 article. View Online2017 WCN 2017

Congresses

2016

AAPS

Nwachukwu F, et al. Determination of Xanthan Gum in Powder blend by Viscometry. Denver, CO: Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists 2016. View Online2016 AAPS 2016

Congresses

2016

AHA

Matsushita K, et al. Potassium Levels and Mortality in Patients With Newly Diagnosed Heart Failure: A Nationwide Study of US Veterans. In: Circulation. 2016;134 (Suppl 1):A14859. View Online2016 AHA 2016

Congresses

2016

AHA Epi/Lifestyle

Chen Y, et al. Impact of Serum Potassium on Mortality and Kidney Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study. In: Circulation. 2016;133(Suppl 1):AP217. See Chen et al. Am J Kidney Dis 2017 article.2016 AHA Epi/Lifestyle 2016

Congresses

2016

AMCP

Weir MR, et al. Patiromer Lowers Serum K+ and Prevents Recurrent Hyperkalemia in CKD Patients ≥65 Years of Age on RAAS Inhibitors. In: J Manag Care Spec Pharm. San Francisco, CA: 28th Academy of Managed Care Pharmacy Managed Care and Specialty Pharmacy Annual Meeting. 2016;22(4-a):S110-11. See Weir et al. Am J Med 2018 article.2016 AMCP 2016

Congresses

2016

AMCP

Weir MR, et al. Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer in Hypekalemic Patients with CKD. In: J Manag Care Spec Pharm. San Francisco, CA: 28th Academy of Managed Care Pharmacy Managed Care and Specialty Pharmacy Annual Meeting. 2016;22(4-a):S111-12. See Weir et al. J Hypertens 2017 article.2016 AMCP 2016

Congresses

2016

AMCP Nexus

Polson M, et al. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. In: J Manag Care Spec Pharm. National Harbor, MD: Annual Academy of Managed Care Pharmacy Nexus 2016. 2016;22(10-a Suppl):S41. See Polson et al. J Manag Care Spec Pharm 2017 article.2016 AMCP Nexus 2016

Congresses

2016

ASH

Epstein M, et al. Patiromer treatment of hyperkalemic resistant hypertension patients with diabetic kidney disease on RAASi normalizes serum potassium and reducing discontinuations secondary to hyperkalemia over 1 year (AMETHYST - DN). In: J Am Soc Hypertens. New York, NY: 31st Annual Scientific Meeting of the American Society of Hypertension. 2016;10(4S):e16. View Online2016 ASH 2016

Congresses

2016

ASHP

Brenner M, et al. Palatability Profile of Patiromer, a Once-Daily Oral Potassium Binder for the Treatment of Hyperkalemia. American Society of Health-System Pharmacists 2016 Mid-year Meeting.2016 ASHP 2016

Congresses

2016

ASHP

Smith DH, et al. Hyperkalemia Related to Treatments in Heart Failure Patients was Associated with Excess Days in Hospital. American Society of Health-System Pharmacists 2016 Mid-year Meeting. View Online2016 ASHP 2016

Congresses

2016

ASHP

Benton W, et al. Effect of Patiromer on Serum Potassium in Hyperkalemic Patients with Type 2 Diabetes on RAAS Inhibitors ± Insulin Therapy for Diabetes. American Society of Health-System Pharmacists 2016 Mid-year Meeting. View Online2016 ASHP 2016

Congresses

2016

ASN – Kidney Week

Brunelli SM, et al. Serum Potassium and Clinical Outcomes among Hemodialysis Patients: Impact of the Long Interdialytic Interval. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):595A. See Brunelli et al. Am J Kidney Dis 2017 article.2016 ASN – Kidney Week 2016

Congresses

2016

ASN – Kidney Week

Golestaneh L, et al. Healthcare Cost Rises Exponentially by Stage of Chronic Kidney Disease. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):843A. See Golestaneh et al. AJMC 2017 article.2016 ASN – Kidney Week 2016

Congresses

2016

ASN – Kidney Week

Weir MR, et al. Aldosterone, Renin and Blood Pressure during Patiromer Treatment of Hyperkalemia in CKD. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):202A. See Weir et al. Kidney Int 2016 article.2016 ASN – Kidney Week 2016

Congresses

2016

ASN – Kidney Week

Kovesdy CP, et al. Serum Potassium and the Risk of Adverse Outcomes: A CKD Prognosis Consortium Meta-Analysis. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):201A. See Kovesdy et al. Eur Heart J 2018 article.2016 ASN – Kidney Week 2016

Congresses

2016

ASN – Kidney Week

Weir MR, et al. Evaluation of Potential Pharmacodynamic Interactions with Antihypertensive Drugs Given Concomitantly with Patiromer: Pooled Analysis of Phase 2/3 Clinical Trials. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):202A-203A. Free online access at: See Weir et al. Kidney Int 2016 article2016 ASN – Kidney Week 2016

Congresses

2016

ASN – Kidney Week

Brunelli SM, et al. Association of Potassium Gradient with Near-Term Clinical Outcomes in Hemodialysis Patients. In: J Am Soc Nephrol. Chicago, IL: 49th Annual Meeting of the American Society of Nephrology. 2016;27(Abstract Suppl):976A. See Brunelli et al. Nephrol Dial Transplant 2017 article.2016 ASN – Kidney Week 2016

Congresses

2016

CVCT

Mayo M, et al. Evaluation of the Potential Pharmacodynamic Interactions with Antihypertensive Drugs Given Concomitantly with Patiromer: Pooled Anlysis of Phase 2/3 Clinical Trials. 13th Global Cardiovascular Clinical Trials Forum. (encore of ASN poster). See Lesko et al. J Cardiovasc Pharmacol Ther 2017 article.2016 CVCT 2016

Congresses

2016

CVCT

Wilson D, et al. Strategy for Improved BP Control in Resistant Hypertension with Diabetic Kidney Disease. 13th Global Cardiovascular Clinical Trials Forum. (encore of NKF poster)2016 CVCT 2016

Congresses

2016

CVCT

Gross C, et al. Aldosterone, Renin, and Blood Pressure During Patiromer Treatment of Hyperkalemia in CKD. 13th Global Cardiovascular Clinical Trials Forum. (encore of ASN poster). See Weir et al. Kidney Int 2016 article.2016 CVCT 2016

Congresses

2016

EASD

Rossignol P, et al. Insulin therapy for diabetes does not modify the effect of patiromer on serum potassium in hyperkalaemic patients with type 2 diabetes on RAAS inhibitors. In: Diabetologia. Abstracts of the 52nd EAST Annual Meeting. 2016;59(Suppl 1):S503-04. View Online2016 EASD 2016

Congresses

2016

ERA-EDTA

Epstein M, et al. Patiromer Protected Against Recurrent Hyperkalemia for Up to 52 Weeks in Patients with Diabetic Kidney Disease (DKD) Receiving Combined RAAS Inhibitor Therapy. In: Nephrol Dial Transplant. Vienna, Austria: 53rd ERA-EDTA Congress. 2016;31(suppl. 1):i4. View Online2016 ERA-EDTA 2016

Congresses

2016

ERA-EDTA

Bushinsky D, et al. Effect of the Potassium Binding Polymer Patiromer on Urine Sodium Excretion in Healthy. In: Nephrol Dial Transplant. Vienna, Austria: 53rd ERA-EDTA Congress. 2016;31(suppl. 1):i3-i4. See Bushinsky et al. Clin J Am Soc Nephrol 2016 article.2016 ERA-EDTA 2016

Congresses

2016

ISH

Weir MR, et al. Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer in Hyperkalemic Patients with CKD. In: J Hypertens. Seoul, South Korea: 26th Scientific Meeting of the International Society of Hypertension. 2016;34(e-Suppl 1):e229. See Weir et al. J Hypertens 2017 article.2016 ISH 2016

Congresses

2016

ISH

Weir MR, et al. Treatment with Patiromer Resulted in Decreases in Aldosterone in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK. In: J Hypertens. Seoul, South Korea: 26th Scientific Meeting of the International Society of Hypertension. 2016;34(e-Suppl 1):e228-29. See Weir et al. Kidney Int 2016 article2016 ISH 2016

Congresses

2016

NKF

Bushinsky D, et al. Patiromer Decreases Serum Potassium in Patients on HD. In: Am J Kid Dis. Boston, MA. 25th Annual Spring Clinical Meetings of the National Kidney Foundation. 2016;67(5):A31. See Bushinsky et al. Am J Nephrol 2016 article.2016 NKF 2016

Congresses

2016

NKF

Epstein M, et al. Strategy for Improved Blood Pressure (BP) Control in Resistant Hypertension (RH) With Diabetic Kidney Disease (DKD). In: Am J Kid Dis. Boston, MA. 25th Annual Spring Clinical Meetings of the National Kidney Foundation. 2016;67(5):A43. View Online2016 NKF 2016

Congresses

2016

NKF

Grams M, et al. Racial Differences in the Prevalence, Patterns, and Mortality Associated With Hyperkalemia Among 2.7 Million Veterans. In: Am J Kid Dis. Boston, MA. 25th Annual Spring Clinical Meetings of the National Kidney Foundation. 2016;67(5):A50. See Chen et al. Am J Kidney Dis 2017 article.2016 NKF 2016

Congresses

2016

NKF

Bushinsky D, et al. Effect of Patiromer on Urine Calcium and Phosphate Excretion in Healthy Adults. In: Am J Kid Dis. Boston, MA. 25th Annual Spring Clinical Meetings of the National Kidney Foundation. 2016;67(5):A30. See Bushinsky et al. Clin J Am Soc Nephrol 2016 article.2016 NKF 2016

Congresses

2016

WCIRDC

Labonté E, et al. Insulin Therapy for Diabetes Does Not Modify the Effect of Patiromer on Serum Potassium in Hyperkalemic Patients with Type 2 Diabetes on RAAS Inhibitors. In: Endocr Pract. Los Angeles, CA. 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascualr Disease. 2017;23(1):41A-42A. View Online2016 WCIRDC 2016

Congresses

2015

AAHFN

Pitt B, et al. 1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors. In: Heart Lung. New Orleans, LA: 11th Annual Conference of the American Association of Heart Failure Nurses. 2015;44(6):549-550. See Pitt et al. ESC Heart Fail 2018 article.2015 AAHFN 2015

Congresses

2015

AAHFN

Pitt B, et al. Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK. In: Heart Lung. New Orleans, LA: 11th Annual Conference of the American Association of Heart Failure Nurses. 2015;44(6):550. See Pitt et al. Eur J Heart Fail 2015 article.2015 AAHFN 2015

Congresses

2015

AAHFN

Bushinksy D, et al. Patiromer induced a rapid onset of action and sustained potassium (K+) lowering throughout the dosing period in CKD patients with hyperkalemia. In: Heart Lung. New Orleans, LA: 11th Annual Conference of the American Association of Heart Failure Nurses. 2015;44(6):550. See Bushinsky et al. Kidney Int 2015 article.2015 AAHFN 2015

Congresses

2015

ACC

Pitt B, et al. One-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors. In: J Am Coll Cardiol. Chicago, IL: 64th Annual Scientific Session and Expo of the American College of Cardiology. 2015;65(10-S):A855. See Pitt et al. ESC Heart Fail 2018 article.2015 ACC 2015

Congresses

2015

ADA

Weir MR, et al. Patiromer lowered serum K+ in hyperkalemic patients with diabetic kidney disease on RAAS inhibitors. In: Diabetes. Boston, MA: 75th Scientific Sessions of the American Diabetes Association. 2015;64(suppl 1):A339. View Online2015 ADA 2015

Congresses

2015

AHA

Epstein M, et al. Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASI, With Diabetic Kidney Disease. In: Circulation. Orlando, FL: 88th Scientific Session of the American Heart Association. 2015;132(suppl 3):A14271. View Online2015 AHA 2015

Congresses

2015

AHA Council on Hypertension

Weir MR, et al. Patiromer Decreased Aldosterone, Urine Albumin/Creatinine Ratio, and Blood Pressure in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK. In: Hypertension. Washington, DC: American Heart Association Council on Hypertension Scientific Sessions. 2015;66(suppl 1):AP602. See Weir et al. Kidney Int 2016 article.2015 AHA Council on Hypertension 2015

Congresses

2015

AMCP

Knispel J, et al. Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure and /or Chronic Kidney Disease: The Role of Hyperkalemia. In: J Manag Care Spec. San Diego, CA: AMCP 27th Annual Meeting & Expo Meeting Abstracts. 2015;21(4-a):S71. See Epstein et al. Am J Manag Care 2016 article.2015 AMCP 2015

Congresses

2015

AMCP

Knispel J, et al. Patients with Cardiorenal Comorbidities on Submaximum Doses or Who Discontinued Renin-Angiotensin-Aldosterone System Inhibitors Manifested Significantly Worse Cardiorenal Outcomes than Patients on Maximum Doses of RAASi. In: J Manag Care Spec. San Diego, CA: AMCP 27th Annual Meeting & Expo Meeting Abstracts. 2015;21(4-a):S48-49. See Epstein et al. Am J Manag Care 2016 article.2015 AMCP 2015

Congresses

2015

ASH

Weir MR, et al. Patiromer Decreases Aldosterone, With Decreases in Urine Albumin/Creatinine Ratio and Systolic Blood Pressure, in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK. Presented at American Society of Hypertension – 30th Scientific Meeting. See Weir et al. Kidney Int 2016 article.2015 ASH 2015

Congresses

2015

ASH

Weir MR, et al. Patiromer increased time to RAASi discontinuation compared with placebo in advanced CKD patients with hyperkalemia. In: J Am Soc Hypertens. New York, NY: American Society of Hypertension 30th Annual Scientific Meeting. 2015;9(4S) Supplement:e57-58. View Online2015 ASH 2015

Congresses

2015

ASH

Knispel J, et al. Prescribing patterns of renin-angiotensin-aldosterone-system inhibitors are inconsistent with guidelines for treatment of cardiorenal comorbitities. In: J Am Soc Hypertens. New York, NY: American Society of Hypertension 30th Annual Scientific Meeting. 2015;9(4S) Supplement:e21. See Epstein et al. Am J Manag Care 2016 article.2015 ASH 2015

Congresses

2015

ASH

Bakris G, et al. Reduction of serum K+ with patiromer for 1 year in patients with diabetic CKD who developed hyperkalemia while on maximal losartan and/or spironolactone. In: J Am Soc Hypertens. New York, NY: American Society of Hypertension 30th Annual Scientific Meeting. 2015;9(4S) Supplement:e75-76. View Online2015 ASH 2015

Congresses

2015

ASHP

Pitt B, et al. Patiromer reduced serum potassium in hyperkalemic patients with HF and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN. American Society of Health-System Pharmacists 2015 Mid-year Meeting. View Online2015 ASHP 2015

Congresses

2015

ASHP

Bakris G, et al. Patiromer lowered serum potassium for up to 1 year in hyperkalemic patients with diabetes and advanced kidney disease on RAASi inhibitors. American Society of Health-System Pharmacists 2015 Mid-year Meeting. View Online2015 ASHP 2015

Congresses

2015

ASN – Kidney Week

Bushinsky DA, et al. Wide range in variation in serum potassium in hyperkalemic patients with CKD, response to a fixed 60 meq potassium diet. In: J Am Soc Nephrol. San Diego, CA: 48th Annual Meeting of the American Society of Nephrology - Kidney Week. 2015;26(abstract suppl):845A. View Online2015 ASN – Kidney Week 2015

Congresses

2015

ASN – Kidney Week

Chang AR, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large healthcare System. In: J Am Soc Nephrol. San Diego, CA: 48th Annual Meeting of the American Society of Nephrology - Kidney Week. 2015;26(abstract suppl):845A. See Chang et al. Hypertension 2016 article.2015 ASN – Kidney Week 2015

Congresses

2015

ASN – Kidney Week

Weir MR, et al. Chronic diuretic therapy does not impair the effectiveness of patiromer in hyperkalemic patients with CKD. In: J Am Soc Nephrol. San Diego, CA: 48th Annual Meeting of the American Society of Nephrology - Kidney Week. 2015;26(abstract suppl):240A. See Weir et al. J Hypertens 2017 article.2015 ASN – Kidney Week 2015

Congresses

2015

ASN – Kidney Week

Weir MR, et al. Patiromer lowers serum K+ and prevents recurrent hyperkalemia in CKD patients ≥65 years of age on RAAS inhibitors. In: J Am Soc Nephrol. San Diego, CA: 48th Annual Meeting of the American Society of Nephrology - Kidney Week. 2015;26(abstract suppl):10A. See Weir et al. Am J Med 2018 article.2015 ASN – Kidney Week 2015

Congresses

2015

CVCT

Bakris G, et al. Patiromer Lowered Serum Potassium for Up to 1 Year in Hyperkalemic Patients with Diabetes and Advanced Kidney Disease on RAAS Inhibitors. 12th Global Cardiovascular Clinical Trials Forum.2015 CVCT 2015

Congresses

2015

EASD

Weir MR, et al. Patiromer lowers serum potassium in patients with elevated potassium and diabetes and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN. In: Diabetologia. Stockholm, Sweden: 51st Annual Meeting of the European Association for the Study of Diabetes. 2015;58(suppl 1):S533-S534. View Online2015 EASD 2015

Congresses

2015

ERA-EDTA

Bakris G, et al. Patiromer lowered serum potassium for up to 1 year in hyperkalemic patients with diabetes and advanced kidney disease on RAAS inhibitors. In: Nephrol Dial Transplant. London, UK. 52nd Congress of the European Renal Association with the European Dialysis and Transplant Association. 2015;30(suppl 3):iii51-iii52. View Online2015 ERA-EDTA 2015

Congresses

2015

ESC

Pitt B, et al. Patiromer reduced serum K+ in hyperkalemic patients with HF and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN. In: Eur Heart J. London, UK: European Society of Cardiology Congress. 2015;36(suppl 1):318-319. View Online2015 ESC 2015

Congresses

2015

HFA-ESC

Pitt B, et al. Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: results from OPAL-HK. In: Eur J Heart Fail. 2015;17(S1):90. See Pitt et al. Eur J Heart Fail 2015 article.2015 HFA-ESC 2015

Congresses

2015

HFA-ESC

Pitt B, et al. Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium. In: Eur J Heart Fail. 2015;17(S1):107-108. See Collins et al. Am J Nephrol 2017.2015 HFA-ESC 2015

Congresses

2015

HFSA

Pitt B, et al. Patiromer reduces serum K+ in hyperkalemic patients with HF and CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN. In: J Card Fail. National Harbor, MD: 19th Annual Scientific Meeting of the Heart Failure Society of America. 2015;21(8):S107-S108. View Online2015 HFSA 2015

Congresses

2015

ISPOR

Latts LM, et al. Hyperkalemia is Highly Prevalent in Patients With Cardiorenal Comorbitities Compared to Patients Without These Comorbidities. In: Values in Health. 2015;18(3):A135. View Online2015 ISPOR 2015

Congresses

2015

NKF

Weir MR, et al. Patiromer Reduced Recurrent Hyperkalemia in Advanced CKD Patients on RAASI. In: Am J Kid Dis. Grapevine, TX. 24th Annual Spring Clinical Meetings of the National Kidney Foundation. 2015;65(4):A90. View Online2015 NKF 2015

Congresses

2015

WCN

Epstein M, et al. Mechanism of Action of Patiromer For Oral Suspension: Increases Fecal K[plus] Excretion in Health Subjects Independent of Race. World Congress of Nephrology, 2015. Abstract SAT-218. View Online2015 WCN 2015

Congresses

2015

WCN

Epstein M, et al. Patiromer produces prompt and sustained reductions in Serum K. World Congress of Nephrology, 2015. Abstract SAT-220. View Online2015 WCN 2015

Congresses

2015

WCN

Weir MR, et al. Patiromer For Oral Suspension Reduced Serum K[plus] and Maintained Normokalemia in CKD Patients with Moderate-to-Severe Hyperkalemia on RAAS Inhibitors in the OPAL-HK Study. World Congress of Nephrology, 2015. Abstract SAT-217. View Online2015 WCN 2015

Congresses

2015

WCN

Epstein M, et al. Attainment of Normokalemia in Patients With Chronic Kidney Disease and Moderate to Severe Hyperkalemia on RAAS Inhibitors: Clinical Trial Results With Patiromer. World Congress of Nephrology, 2015. Abstract SAT-219. View Online2015 WCN 2015

Congresses

2014

AHA

Pitt B, et al. Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium. In: Circulation. Chicago, IL: 87th Scientific Session of the American Heart Association. 2014;130(suppl 2):A13320. See Collins et al. Am J Nephrol 2017 article.2014 AHA 2014

Congresses

2014

ASN – Kidney Week

Bakris B, et al. Effect of patiromer on hyperkalemia in patients with diabetic nephropathy: results of a 1-year randomized trial. In: J Am Soc Nephrol. Philadelphia, PA: 47th Annual Meeting of the American Society of Nephrology - Kidney Week. 2014; 25(abstract suppl):B5. See Bakris et al. JAMA 2015 article.2014 ASN – Kidney Week 2014

Congresses

2014

ASN – Kidney Week

Bushinsky DA, et al. Patiromer induced a rapid onset of action and sustained K+ lowering throughout the dosing period in CKD patients with hyperkalemia. In: J Am Soc Nephrol. Philadelphia, PA: 47th Annual Meeting of the American Society of Nephrology - Kidney Week. 2014; 25(abstract suppl):669A. See Bushinsky et al. Kidney Int 2015 article.2014 ASN – Kidney Week 2014

Congresses

2014

ASN – Kidney Week

Collins AJ, et al. Potassium levels and mortality in patients with CKD. In: J Am Soc Nephrol. Philadelphia, PA: 47th Annual Meeting of the American Society of Nephrology - Kidney Week. 2014; 25(abstract suppl):270A. See Collins et al. Am J Nephrol 2017 article.2014 ASN – Kidney Week 2014

Congresses

2014

ASN – Kidney Week

Weir MR, et al. Patiromer lowers serum K+ and prevents recurrent hyperkalemia in patients with diabetes and CKD on RAAS inhibitors: subgroup results of a phase 3 trial. In: J Am Soc Nephrol. Philadelphia, PA: 47th Annual Meeting of the American Society of Nephrology - Kidney Week. 2014; 25(abstract suppl):550A. View Online2014 ASN – Kidney Week 2014

Congresses

2014

ASN – Kidney Week

Weir MR, et al. Patiromer reduced RAASi dose discontinuations in CKD patients with moderate-to-severe hyperkalemia. In: J Am Soc Nephrol. Philadelphia, PA: 47th Annual Meeting of the American Society of Nephrology - Kidney Week. 2014; 25(abstract suppl):555A. . See Weir et al. NEJM 2015 article.2014 ASN – Kidney Week 2014

Congresses

2014

HFSA

Pitt B, et al. Patiromer lowers serum potassium and prevents recurrently hyperkalemia in patients with heart failure and chronic kidney disease when treated with renin angiotensin aldosterone system inhibitors. Results from a two-art Phase 3 trial. Oral presentation at Heart Failure Society of America (HFSA) 2014 annual congress. Las Vegas, NV, September 14-17, 2014. See Pitt et al. Eur J Heart Fail 2015 article2014 HFSA 2014

Congresses

2010

ASN – Renal Week

Bushinsky D, et al. RLY5016: A Novel, Effective, Non-Absorbed, Oral Polymer for the Control of Serum Potassium in Heart Failure and Chronic Kidney Disease. In: J Am Soc Nephrol. Denver, CO: 43rd Annual Meeting of the American Society of Nephrology - Renal Week. 2010;21(abstract suppl):483A. See Pitt et al. Eur Heart J 2011 article.2010 ASN – Renal Week 2010

Congresses

2010

ASN – Renal Week

Cope J, et al. RYL5016: A new, effective, nonabsorbed, therapeutic polymer to control serum potassium. In: J Am Soc Nephrol. Denver, CO: 43rd Annual Meeting of the American Society of Nephrology - Renal Week. 2010;21(abstract suppl):483A. See Li et al. J Cardiovasc Pharmacol Ther 2016 article.2010 ASN – Renal Week 2010

Congresses

2010

ASN – Renal Week

Huang IZ, et al. RLY5016: A novel, non-absorbed, therapeutic polymer for serum potassium control. In: J Am Soc Nephrol. Denver, CO: 43rd Annual Meeting of the American Society of Nephrology - Renal Week. 2010;21(abstract suppl):482A. See Bushinsky et al. Clin J Am Soc Nephrol 2016 article.2010 ASN – Renal Week 2010